References
- Bjornsson E, Chari ST, Smyrk TC, et al. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology. 2007;45:1547–1554.
- Iwasaki S, Kamisawa T, Koizumi S, et al. Assessment in steroid trial for IgG4-related sclerosing cholangitis. Adv Med Sci. 2015;60:211–215.
- Yata M, Suzuki K, Furuhashi N, et al. Comparison of the multidetector-row computed tomography findings of IgG4-related sclerosing cholangitis and extrahepatic cholangiocarcinoma. Clin Radiol. 2016;71:203–210.
- Lin J, Cummings OW, Greenson JK, et al. IgG4-related sclerosing cholangitis in the absence of autoimmune pancreatitis mimicking extrahepatic cholangiocarcinoma. Scand J Gastroenterol. 2015;50:447–453.
- Li H, Sun L, Brigstock DR, et al. IgG4-related sclerosing cholangitis overlapping with autoimmune hepatitis: report of a case. Pathol Res Pract. 2017;213:565–569.
- Nirula A, Glaser SM, Kalled SL, et al. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol. 2011;23:119–124.
- Smit WL, Culver EL, Chapman RW. New thoughts on immunoglobulin G4-related sclerosing cholangitis. Clin Liver Dis. 2016;20:47–65.
- Bjornsson E, Chari S, Silveira M, et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther. 2011;18:198–205.
- Chapman RW. Primary sclerosing cholangitis. Medicine. 2015;43:648–652.
- Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19:536–542.
- Campochiaro C, Ramirez GA, Bozzolo EP, et al. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. Scand J Rheumatol. 2016;45:135–145.
- Kamisawa T, Zen Y, Pillai S, et al. IgG4-related disease. Lancet. 2015;385:1460–1471.
- Lian M, Li B, Xiao X, et al. Comparative clinical characteristics and natural history of three variants of sclerosing cholangitis: IgG4-related SC, PSC/AIH and PSC alone. Autoimmun Rev. 2017.
- Nakazawa T, Shimizu S, Naitoh I. IgG4-related sclerosing cholangitis. Semin Liver Dis. 2016;36:216–228.
- Di Sabatino A, Biagi F, Lenzi M, et al. Clinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases. Dig Liver Dis. 2017;49:947–956.
- Tanaka A, Tazuma S, Okazaki K, et al. Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis. Clin Gastroenterol Hepatol. 2017;15:920–926.e3.
- Martínez-Valle F, Fernández-Codina A, Pinal-Fernández I, et al. IgG4-related disease: evidence from six recent cohorts. Autoimmun Rev. 2017;16:168–172.
- Nakazawa T, Naitoh I, Hayashi K, et al. Diagnosis of IgG4-related sclerosing cholangitis. World J Gastroenterol. 2013;19:7661–7670.
- Rahnemai-Azar AA, Weisbrod A, Dillhoff M, et al. Intrahepatic cholangiocarcinoma: molecular markers for diagnosis and prognosis. Surg Oncol. 2017;26:125–137.
- Huggett MT, Culver EL, Kumar M, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014;109:1675–1683.
- Chung BK, Guevel BT, Reynolds GM, et al. Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis. J Autoimmun. 2017;77:45–54.
- Ozaslan E, Efe C, Gokbulut ON. The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Clin Res Hepatol Gastroenterol. 2016;40:553–561.